NVAX Novavax, Inc.
USHealthcareAs of 2026-10-08
Why NVAX matters now
Novavax, Inc. (NVAX) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.01 with -1.87% on the session and $1.81B in market capitalization; recent performance reads 1-month +2.58% and YTD +35.86%.
The latest financial table shown here is Q1 2026, with revenue of $139.5M, net income of $-9.5M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E 2.95 and FCF yield -6.5%.
The latest indexable market news headline is "Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $18.00; recent insider activity includes Newton Charles W. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
2.95
PEG
0.01
P/B
-10.30
P/S
2.52
EV/EBITDA
-37.22
DCF Value
$-77.37
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.6%
Operating Margin
-11.2%
Net Margin
-14.7%
ROE
89.7%
ROA
-8.4%
ROIC
-9.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $139.5M | $-9.5M | $-0.06 |
| Q4 2025 | $147.1M | $17.5M | $0.11 |
| FY 2025 | $1.12B | $440.3M | $2.54 |
| Q3 2025 | $70.4M | $-202.4M | $-1.25 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$18.00
Target (Median)
$18.00
Target Range
$11.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.41
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.